Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - valganciclovir hydrochloride 496,3 mg - eq. valganciclovir 450 mg - film-coated tablet - 450 mg - valganciclovir hydrochloride 496.3 mg - valganciclovir

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - ganciclovir, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide - ganciclovir alphapharm (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir alphapharm (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - ganciclovir, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide - ganciclovir mylan (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir mylan (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - ganciclovir, quantity: 500 mg - injection, powder for - excipient ingredients: sodium hydroxide - ganciclovir agila (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir agila (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg - tablet, film coated - excipient ingredients: crospovidone; stearic acid; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; allura red ac aluminium lake; macrogol 400 - valganciclovir cw is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir cw is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: stearic acid; silicon dioxide; crospovidone; croscarmellose sodium; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: crospovidone; povidone; microcrystalline cellulose; croscarmellose sodium; silicon dioxide; stearic acid; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - valganciclovir hydrochloride, quantity: 496.3 mg (equivalent: valganciclovir, qty 450 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; silicon dioxide; stearic acid; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in adult patients with acquired immunodeficiency syndrome (aids).,valganciclovir is indicated for the prophylaxis of cmv disease in adult and paediatric solid organ transplantation (sot) patients who are at risk.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Canada - English - Health Canada

cheplapharm arzneimittel gmbh - ganciclovir (ganciclovir sodium) - powder for solution - 500mg - ganciclovir (ganciclovir sodium) 500mg - nucleosides and nucleotides